AR033624A1 - Derivados del dihidro-imidazo[4,5-e]indol y de la 7h-pirrolo[3,2-f]quinoxalina en calidad de ligandos nicotinicos del receptor para acetilcolina y/o de ligandos serotoninergicos, un procedimiento para su preparacion, las composiciones farmaceuticas que los contienen, y el empleo de los mismos para p - Google Patents
Derivados del dihidro-imidazo[4,5-e]indol y de la 7h-pirrolo[3,2-f]quinoxalina en calidad de ligandos nicotinicos del receptor para acetilcolina y/o de ligandos serotoninergicos, un procedimiento para su preparacion, las composiciones farmaceuticas que los contienen, y el empleo de los mismos para pInfo
- Publication number
- AR033624A1 AR033624A1 ARP020101529A ARP020101529A AR033624A1 AR 033624 A1 AR033624 A1 AR 033624A1 AR P020101529 A ARP020101529 A AR P020101529A AR P020101529 A ARP020101529 A AR P020101529A AR 033624 A1 AR033624 A1 AR 033624A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- ligands
- cycloalkyl
- mono
- disease
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 2
- 230000002295 serotoninergic effect Effects 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000000044 Amnesia Diseases 0.000 abstract 2
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 abstract 2
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 230000000862 serotonergic effect Effects 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- JOUGPRUYMOPGKX-UHFFFAOYSA-N 7h-pyrrolo[3,2-f]quinoxaline Chemical compound C1=CN=C2C(C=CN3)=C3C=CC2=N1 JOUGPRUYMOPGKX-UHFFFAOYSA-N 0.000 abstract 1
- 208000031091 Amnestic disease Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000020358 Learning disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 206010057852 Nicotine dependence Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004373 acetylcholine Drugs 0.000 abstract 1
- 230000002164 acetylcholinergic effect Effects 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000006986 amnesia Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 230000006931 brain damage Effects 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 201000003723 learning disability Diseases 0.000 abstract 1
- 210000004558 lewy body Anatomy 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 231100000167 toxic agent Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10121215A DE10121215A1 (de) | 2001-04-30 | 2001-04-30 | Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033624A1 true AR033624A1 (es) | 2003-12-26 |
Family
ID=7683301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101529A AR033624A1 (es) | 2001-04-30 | 2002-04-26 | Derivados del dihidro-imidazo[4,5-e]indol y de la 7h-pirrolo[3,2-f]quinoxalina en calidad de ligandos nicotinicos del receptor para acetilcolina y/o de ligandos serotoninergicos, un procedimiento para su preparacion, las composiciones farmaceuticas que los contienen, y el empleo de los mismos para p |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7279496B2 (enExample) |
| EP (1) | EP1383774B1 (enExample) |
| JP (1) | JP4593879B2 (enExample) |
| AR (1) | AR033624A1 (enExample) |
| AT (1) | ATE394404T1 (enExample) |
| AU (1) | AU2002310904B2 (enExample) |
| CA (1) | CA2445834C (enExample) |
| CZ (1) | CZ20033195A3 (enExample) |
| DE (2) | DE10121215A1 (enExample) |
| ES (1) | ES2303857T3 (enExample) |
| HU (1) | HUP0304046A2 (enExample) |
| SK (1) | SK14472003A3 (enExample) |
| WO (1) | WO2002088143A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011858A (es) * | 2002-05-30 | 2005-03-31 | Neurosearch As | Quinuclidinas sustituidas en la posicion 3 y su uso. |
| US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
| BRPI0607517A2 (pt) * | 2005-04-13 | 2009-09-08 | Neuraxon Inc | compostos de indol substituìdo, composição farmacêutica compreendendo o mesmo, método para tratar e uso do mesmo |
| US7897766B2 (en) * | 2005-09-23 | 2011-03-01 | Abbott Laboratories | Amino-aza-adamantane derivatives and methods of use |
| TW200808780A (en) * | 2006-04-13 | 2008-02-16 | Neuraxon Inc | 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity |
| CA2705422A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
| KR20100103799A (ko) * | 2007-11-16 | 2010-09-28 | 네우렉슨 인코포레이티드 | 내장통을 치료하기 위한 인돌 화합물 및 방법 |
| WO2009062318A1 (en) * | 2007-11-16 | 2009-05-22 | Neuraxon, Inc. | 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009565A1 (de) * | 1990-03-24 | 1991-09-26 | Merck Patent Gmbh | Indolderivate |
| EP0664807B1 (en) | 1992-10-13 | 1997-09-10 | Warner-Lambert Company | Quinoxalinedione derivatives as eaa antagonists |
| DK0698025T3 (da) | 1993-05-13 | 1998-08-24 | Neurosearch As | Ampa-antagonister samt fremgangsmåde til behandling dermed |
| US5843945A (en) | 1993-05-13 | 1998-12-01 | Neurosearch A/S | AMPA antagonists and a method of treatment |
| NZ321172A (en) * | 1995-10-03 | 2000-02-28 | Scripps Research Inst | CBI analogs of CC-1065 and the duocarmycins |
| CA2321559A1 (en) * | 1998-02-26 | 1999-09-02 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrrolobenzimidazoles for treating inflammatory diseases |
-
2001
- 2001-04-30 DE DE10121215A patent/DE10121215A1/de not_active Withdrawn
-
2002
- 2002-03-30 EP EP02735200A patent/EP1383774B1/en not_active Expired - Lifetime
- 2002-03-30 AT AT02735200T patent/ATE394404T1/de not_active IP Right Cessation
- 2002-03-30 AU AU2002310904A patent/AU2002310904B2/en not_active Ceased
- 2002-03-30 CZ CZ20033195A patent/CZ20033195A3/cs unknown
- 2002-03-30 WO PCT/EP2002/003582 patent/WO2002088143A2/en not_active Ceased
- 2002-03-30 US US10/476,234 patent/US7279496B2/en not_active Expired - Fee Related
- 2002-03-30 CA CA2445834A patent/CA2445834C/en not_active Expired - Fee Related
- 2002-03-30 ES ES02735200T patent/ES2303857T3/es not_active Expired - Lifetime
- 2002-03-30 JP JP2002585441A patent/JP4593879B2/ja not_active Expired - Fee Related
- 2002-03-30 SK SK1447-2003A patent/SK14472003A3/sk unknown
- 2002-03-30 DE DE60226428T patent/DE60226428D1/de not_active Expired - Lifetime
- 2002-03-30 HU HU0304046A patent/HUP0304046A2/hu unknown
- 2002-04-26 AR ARP020101529A patent/AR033624A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60226428D1 (de) | 2008-06-19 |
| US7279496B2 (en) | 2007-10-09 |
| WO2002088143A2 (en) | 2002-11-07 |
| CA2445834A1 (en) | 2002-11-07 |
| US20040142935A1 (en) | 2004-07-22 |
| ATE394404T1 (de) | 2008-05-15 |
| EP1383774B1 (en) | 2008-05-07 |
| SK14472003A3 (sk) | 2004-04-06 |
| AU2002310904B2 (en) | 2008-01-10 |
| EP1383774A2 (en) | 2004-01-28 |
| WO2002088143A3 (en) | 2003-01-23 |
| DE10121215A1 (de) | 2002-10-31 |
| JP4593879B2 (ja) | 2010-12-08 |
| CA2445834C (en) | 2011-06-28 |
| CZ20033195A3 (cs) | 2004-02-18 |
| ES2303857T3 (es) | 2008-09-01 |
| HUP0304046A2 (hu) | 2004-04-28 |
| JP2004529936A (ja) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2820362C (en) | Substituted pyrazolopyrimidines as glucocerebrosidase activators | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| BR0312312A (pt) | Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários | |
| AR038419A1 (es) | Derivados de piridina y quinolina | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| AR010378A1 (es) | Novedosos compuestos con efecto analgesico, uso de los mismos para la preparacion de un medicamento y como agente de diagnostico, composicion farmaceutica, proceso para la preparacion de dichos compuestos y compuestos intermediarios | |
| PE20010130A1 (es) | Derivados de 3(5)-amino-pirazol y procedimiento para su preparacion | |
| AR060633A1 (es) | Derivados de furo[3, 2-d]pirimidina, furo[2, 3-d]pirimidina, tieno[3, 2-d]pirimidina y tieno[2, 3-d]pirimidina, metodos para su preparacion, composiciones farmaceuticas y obtencion de las mismas, el uso de estos derivados en la fabricacion de medicamentos, kits y productos para el tratamiento de enf | |
| AR037680A1 (es) | Antagonistas del receptor de adenosina a2a de 5-amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-c]-pirimidinas sustituidas, composiciones farmaceuticas que los comprenden, el uso de dichos compuestos, solos o en combinacion para la elaboracion de un medicamento utiles para el tratamiento de enfermedades d | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
| AR033624A1 (es) | Derivados del dihidro-imidazo[4,5-e]indol y de la 7h-pirrolo[3,2-f]quinoxalina en calidad de ligandos nicotinicos del receptor para acetilcolina y/o de ligandos serotoninergicos, un procedimiento para su preparacion, las composiciones farmaceuticas que los contienen, y el empleo de los mismos para p | |
| PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
| EP2480081A1 (en) | Bridged heterocyclic compounds and methods of use | |
| AR043051A1 (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| KR20150068923A (ko) | 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 아자인돌 유도체 및 이를 포함하는 약제학적 조성물 | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| ECSP034851A (es) | Derivados imidazo[1,5-a]pirimido[5,4-d]benzazepina como moduladores del receptor gaba a | |
| AR017189A1 (es) | Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento | |
| AR056762A1 (es) | (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |